Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 202,510 | 176,306 | 127,055 | 173,729 | 150,619 |
| Marketable Securities | 222,738 | 311,279 | 367,385 | 436,296 | 470,989 |
| Receivables | 112,543 | 124,464 | 98,839 | 121,801 | 93,301 |
| Inventories | 52,200 | 46,498 | 46,031 | 45,007 | 43,334 |
| TOTAL | $643,206 | $719,788 | $699,155 | $817,123 | $799,608 |
| Non-Current Assets | |||||
| PPE Net | 249,961 | 255,763 | 260,906 | 265,929 | 272,448 |
| Investments And Advances | 22,067 | 51,454 | 68,563 | 135,004 | 203,086 |
| Intangibles | 217,349 | 219,139 | 220,930 | 222,720 | 209,348 |
| Other Non-Current Assets | 57,862 | 60,121 | 62,373 | 62,680 | 53,873 |
| TOTAL | $547,239 | $586,477 | $612,772 | $686,333 | $738,755 |
| Total Assets | $1,190,445 | $1,306,265 | $1,311,927 | $1,503,456 | $1,538,363 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 40,573 | 34,242 | 47,450 | 38,756 | 35,990 |
| Accrued Expenses | 220,526 | 180,792 | 173,007 | 240,973 | 185,028 |
| Other current liabilities | 66,781 | 66,444 | 60,724 | 54,127 | 53,566 |
| TOTAL | $340,022 | $293,244 | $291,668 | $344,153 | $285,008 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 811,206 | 831,677 | 845,955 | 873,948 | 876,470 |
| TOTAL | $841,264 | $861,735 | $876,013 | $904,006 | $906,528 |
| Total Liabilities | $1,181,286 | $1,154,979 | $1,167,681 | $1,248,159 | $1,191,536 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 96,478 | 96,372 | 94,542 | 92,501 | 92,344 |
| Common Shares | 96 | 96 | 94 | 92 | 92 |
| Retained earnings | -4,403,288 | -4,222,875 | -4,107,924 | -3,956,844 | -3,823,459 |
| Other shareholders' equity | 8,820 | 7,732 | 7,659 | 3,357 | 4,896 |
| TOTAL | $9,159 | $151,286 | $144,246 | $255,297 | $346,827 |
| Total Liabilities And Equity | $1,190,445 | $1,306,265 | $1,311,927 | $1,503,456 | $1,538,363 |